More on BofA's MannKind (MNKD -0.7%) downgrade: Price target raised to $8 from $5 as "model adjustments" raise the output from the bank's discounted cash flow calculation. Analyst Steve Byrne notes that while he "continues to expect favorable phase 3 data in coming months … the shares as fairly valued." Byrne also says his "penetration forecasts for Afrezza in Type 1 and 2 patients are unchanged."
More on BofA's MannKind (MNKD -0.7%) downgrade: Price target raised to $8 from $5 as "model...
Recommended For You
About MNKD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MNKD | - | - |
MannKind Corporation |